Product Information
RASAGILINE MESYLATE 0.5 MG TAB is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5209 per EA under NDC 00093306056. Its NADAC has been published 481 times since Jul 19, 2017.
FDA first approved this application on May 16, 2006. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093306056
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RASAGILINE MESYLATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021641FDA Approved
5/16/2006
TE Code
AB
On Market Since
1/3/2017
Pharmacological Classes
Price Statistics
The NADAC for RASAGILINE MESYLATE 0.5 MG TAB has been published 481 times since Jul 19, 2017, and over the history we have for it it has declined 95.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5209 per EA |
|---|---|
| All-time high | $12.3558 (Jan 10, 2018) |
| All-time low | $0.4545 (Aug 19, 2026) |
| 52-week high | $1.2855 |
| 52-week low | $0.4545 |
| Median price | $2.7862 |
| Average price | $3.9161 |
| Largest weekly change | -54.6% (May 22, 2024) |
| Weeks tracked | 481 |
| Tracking since | Jul 19, 2017 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rasagiline market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Monoamine Oxidase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RASAGILINE MESYLATE 0.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for RASAGILINE MESYLATE 0.5 MG TAB, manufactured by Teva Pharmaceuticals USA Inc., is $0.5209 per EA (NDC 00093306056), effective Sep 30, 2026.
How has the price of RASAGILINE MESYLATE 0.5 MG TAB changed over time?
Over the history we have for it, the NADAC for RASAGILINE MESYLATE 0.5 MG TAB has declined 95.1%. It has been tracked across 481 weekly CMS publications since Jul 19, 2017.
What are the highest and lowest recorded NADAC prices for RASAGILINE MESYLATE 0.5 MG TAB?
Since Jul 19, 2017, the NADAC for RASAGILINE MESYLATE 0.5 MG TAB has ranged from a low of $0.4545 (Aug 19, 2026) to a high of $12.3558 (Jan 10, 2018), with a median of $2.7862 per EA.
Are there cheaper alternatives to RASAGILINE MESYLATE 0.5 MG TAB?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RASAGILINE MESYLATE 0.5 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures RASAGILINE MESYLATE 0.5 MG TAB?
RASAGILINE MESYLATE 0.5 MG TAB (NDC 00093306056) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.